{"id": "1adc970c-d433-44d0-aa09-d3834986f7a2", "result": "Contradiction.\n\nThe statement \"there is a 13.2% difference between the results from the two the primary trial cohorts\" is a contradiction of the trial information provided.\n\nTo calculate the difference between the results from the two primary trial cohorts, we can subtract the event-free survival rate in the exemestane arm from the event-free survival rate in the anastrozole arm:\n\n89% - 88% = 1%\n\nTherefore, the difference between the results from the two primary trial cohorts is 1%, not 13.2%.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "6b9162d0-0816-46d4-81af-c60028dcc63b", "result": "Entailment.\n\nThe statement \"Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients with cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal) are excluded. This means that patients with significantly elevated ejection fraction would be excluded from the primary trial.\n\nThe secondary trial eligibility criteria state that premenopausal women 55 years of age or younger are eligible. This means that patients who are 55 years of age or over would be eligible for the secondary trial, regardless of their ejection fraction.\n\nTherefore, it is possible for patients with significantly elevated ejection fraction to be excluded from the primary trial but still be eligible for the secondary trial if they are 55 years of age or over.\n\nHence, the statement is an entailment of the trial information."}
{"id": "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f", "result": "Contradiction.\n\nThe statement \"a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis\" is a contradiction of the given trial information.\n\nIn the primary trial, only 1 out of 167 participants (0.60%) experienced Enterocolitis. In the secondary trial, none of the 458 participants experienced Enterocolitis.\n\nTherefore, it is not accurate to say that a significant number of participants in both trials suffered from Enterocolitis.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "cc1f712a-2116-4e40-9810-f315e3fa5ff8", "result": "Entailment.\n\nThe statement \"the primary trial does not report the PFS or objective response rate of its patient cohort\" is an entailment of the given trial information.\n\nThe primary trial results section only reports the local control using ipsilateral breast tumor recurrence rates, and does not mention PFS (progression-free survival) or objective response rate.\n\nTherefore, it is accurate to say that the primary trial does not report the PFS or objective response rate of its patient cohort.\n\nHence, the statement is an entailment of the trial information."}
{"id": "904061c0-14fa-4f13-9118-9a41e24fa8eb", "result": "Contradiction.\n\nThe statement \"Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial exclusion criteria state that patients who have received prior treatment with fulvestrant or a PI3K inhibitor are not eligible to participate in the trial.\n\nTherefore, it is not accurate to say that prior treatment with fulvestrant or a PI3K inhibitor will not prevent a patient from participating in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "43ee7645-ce1e-42d5-9a74-3e379f6f367b", "result": "Contradiction.\n\nThe statement \"only patients with a HER2-positive status can take part in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients with unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for the study.\n\nTherefore, it is not accurate to say that only patients with a HER2-positive status can take part in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "0cef8c8e-7986-46c7-a597-c5733a9899c0", "result": "Contradiction.\n\nThe statement \"the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months\" is a contradiction of the given trial information.\n\nThe primary trial results show that the median PFS in cohort 1 was 9.1 months (95% CI: 6.8 to 10.8 months), and the median PFS in cohort 2 was 7.1 months (95% CI: 5.6 to 10.8 months).\n\nTherefore, it is not accurate to say that the shortest PFS in cohort 1 was under 7 months, and the shortest PFS in cohort 2 was just over 7 months.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "43ce26e5-03fa-4e9d-b0eb-6ea356295753", "result": "Entailment.\n\nThe statement \"Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants in both the HER2+ TC cohort and the HER2+ C cohort received treatment for a total of 17 cycles, with each cycle lasting 3 weeks.\n\nTherefore, it is accurate to say that both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks.\n\nHence, the statement is an entailment of the trial information."}
{"id": "3facad41-0221-42f8-834d-470e65c4aad5", "result": "Contradiction.\n\nThe statement \"the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease\" is a contradiction of the given trial information.\n\nThe primary trial results section states that the outcome measurement of the trial is progression-free survival (PFS). PFS is defined as the length of time from the start of treatment until the disease progresses or the patient dies, whichever occurs first.\n\nOverall survival (OS), which is the length of time during and after treatment that a patient survives with the disease, is not mentioned as an outcome measurement in the given trial information.\n\nTherefore, it is not accurate to say that the outcome measurement of the primary trial is OS.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "9cbc00e9-3a2d-4471-a93e-72c95132fb6a", "result": "Entailment.\n\nThe statement \"The only case of congestive heart failure in the primary trial occurred in cohort 1\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there was a total of 1 case of congestive heart failure in the trial, and this case occurred in cohort 1. Cohort 2 had 0 cases of congestive heart failure.\n\nTherefore, it is accurate to say that the only case of congestive heart failure in the primary trial occurred in cohort 1.\n\nHence, the statement is an entailment of the trial information."}
{"id": "8b91cab9-d858-45f3-bf8d-3d6fc55b4818", "result": "Entailment.\n\nThe statement \"The the primary trial results section reports two different measurements\" is an entailment of the given trial information.\n\nThe primary trial results section reports the following two measurements:\n\n1. Proportion of sentinel lymph nodes (SLNs) detected by the Tc method (PTc): 0.86\n2. Proportion of SLNs detected by the ICG method (PICG): 0.95\n\nTherefore, it is accurate to say that the primary trial results section reports two different measurements.\n\nHence, the statement is an entailment of the trial information."}
{"id": "4a75574c-fa86-4e62-a210-81c7b98a3807", "result": "Contradiction.\n\nThe statement \"T4 N2 M4 patients are eligible for the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients with T4 disease with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange, or inflammatory breast cancer are not eligible for the trial.\n\nAdditionally, patients with distant metastases (M4) are also not eligible for the trial.\n\nTherefore, it is not accurate to say that T4 N2 M4 patients are eligible for the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7", "result": "Contradiction.\n\nThe statement \"The the primary trial results section reports two different measurements, for all 3 cohorts\" is a contradiction of the given trial information.\n\nThe primary trial results section only reports the results for a single cohort, which is the Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer) cohort. There is no mention of any other cohorts in the given trial information.\n\nTherefore, it is not accurate to say that the primary trial results section reports two different measurements for all 3 cohorts.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "b0b61978-57db-4a1c-812c-509e8b05f2dc", "result": "Entailment.\n\nThe statement \"both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that both the TNBC cohort and the NSCLC cohort receive the same treatment regimen, which consists of Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24).\n\nThe only difference between the two cohorts is the type of cancer that the patients have. The TNBC cohort has triple-negative breast cancer, while the NSCLC cohort has non-small cell lung cancer.\n\nTherefore, it is accurate to say that both cohorts of the primary trial receive identical interventions, and the difference between the two cohorts is the types of cancer that the patients have.\n\nHence, the statement is an entailment of the trial information."}
{"id": "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1", "result": "Contradiction.\n\nThe statement \"Patients must have a palpable carcinoma to be included in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients with a non-palpable neoplasm are eligible for the trial, as long as the tumor is visible and enhances on prone MRI and is >1 cm in greatest diameter.\n\nTherefore, it is not accurate to say that patients must have a palpable carcinoma to be included in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "fbb62216-2cf2-4813-ad41-12a86940610f", "result": "Entailment.\n\nThe statement \"Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that anaemia was the most common adverse event in both cohort 1 (7/199, 3.52%) and cohort 2 (2/36, 5.56%).\n\nTherefore, it is accurate to say that anaemia was the most common adverse event in cohort 1 and 2 of the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "961a956e-fece-4baa-a2ad-d3a5320bd9d2", "result": "Contradiction.\n\nThe statement \"The shortest PFS in cohort 1 of the primary trial was less than 3 weeks\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that the median PFS in cohort 1 was 8.4 months (95% CI: 7.0 to 9.9 months).\n\nTherefore, it is not accurate to say that the shortest PFS in cohort 1 of the primary trial was less than 3 weeks.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "97fd111c-6969-43ab-93af-b3dff09960e5", "result": "Contradiction.\n\nThe statement \"The adverse events section in the primary trial is reports the incidence rate of 12 different Aes\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section does not report any adverse events, let alone the incidence rate of 12 different adverse events.\n\nTherefore, it is not accurate to say that the adverse events section in the primary trial reports the incidence rate of 12 different adverse events.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "eb1bfb08-eba0-4130-b328-00f56c0f84a6", "result": "Contradiction.\n\nThe statement \"Diarrhoea is the most common adverse event in the primary trial and the secondary trial\" is a contradiction of the given trial information.\n\nIn the primary trial, the most common adverse event is febrile neutropenia (3/65, 4.62%). Diarrhoea is the fourth most common adverse event (5/65, 7.69%).\n\nIn the secondary trial, the most common adverse event is anaemia (6/472, 1.27%). Diarrhoea is not listed as an adverse event in the secondary trial.\n\nTherefore, it is not accurate to say that diarrhoea is the most common adverse event in the primary trial and the secondary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "b1219e71-fbf5-4bba-8a93-a27ae444e3e1", "result": "Entailment.\n\nThe statement \"to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have confirmed hormone receptor positive advanced breast cancer, and that previous treatment for advanced breast cancer is not allowed.\n\nTherefore, it is accurate to say that to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer.\n\nHence, the statement is an entailment of the trial information."}
{"id": "f10f3b84-e039-4a02-a98b-86d149d9a16f", "result": "Entailment.\n\nThe statement \"ongoing flucytosine treatments are not permitted for participants of the primary trial\" is an entailment of the given trial information.\n\nThe primary trial exclusion criteria state that patients who are being treated with flucytosine are not eligible for the trial.\n\nTherefore, it is accurate to say that ongoing flucytosine treatments are not permitted for participants of the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "0ddb07ae-6e70-436d-8723-f609e59c57da", "result": "Entailment.\n\nThe statement \"the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants receive a dose of Pralatrexate 190 mg/m^2 for 2 to 4 weeks.\n\nThis means that the dose of Pralatrexate that each participant receives is calculated based on their body surface area, which is a measure of bodyweight.\n\nTherefore, it is accurate to say that the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight.\n\nHence, the statement is an entailment of the trial information."}
{"id": "c10eea1a-5768-442d-ae07-20b4f8f4b583", "result": "Contradiction.\n\nThe statement \"Only patients with triple negative breast cancer are eligible for the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients with HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies are eligible for the trial.\n\nTherefore, it is not accurate to say that only patients with triple negative breast cancer are eligible for the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "2ef186d0-b4ab-44de-b785-a63e9e95851a", "result": "Entailment.\n\nThe statement \"most participants in the secondary trial and the primary trial did not suffer from Enterocolitis\" is an entailment of the given trial information.\n\nIn the primary trial, only 1 out of 167 participants (0.60%) experienced Enterocolitis. In the secondary trial, none of the 458 participants experienced Enterocolitis.\n\nTherefore, it is accurate to say that most participants in the secondary trial and the primary trial did not suffer from Enterocolitis.\n\nHence, the statement is an entailment of the trial information."}
{"id": "fef5aedb-21c0-4130-b8a3-cb1df5017c7a", "result": "Entailment.\n\nThe statement \"The adverse events section in the primary trial is empty\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows a total of 0 adverse events.\n\nTherefore, it is accurate to say that the adverse events section in the primary trial is empty.\n\nHence, the statement is an entailment of the trial information."}
{"id": "2655c892-216e-4b96-a8f2-6f64403215c5", "result": "Entailment.\n\nThe statement \"there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 4 types of adverse events that had a frequency of 0% in cohort 1: thrombocytopenia, nausea, constipation, and abdominal pain.\n\nTherefore, it is accurate to say that there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "2825d63b-8f22-4fb8-829f-9567845251c6", "result": "Contradiction.\n\nThe statement \"adults and children can take part in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must be 18 years of age or older.\n\nTherefore, it is not accurate to say that adults and children can take part in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "6b35bc10-f591-4b84-abac-40a74be949fa", "result": "Entailment.\n\nThe statement \"Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial\" is an entailment of the given trial information.\n\nThe primary trial exclusion criteria state that patients who have received prior treatment with fulvestrant or a PI3K inhibitor are not eligible for the trial.\n\nTherefore, it is accurate to say that prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "a5baab2c-9c32-4301-a574-4ba5a0c2eb00", "result": "Contradiction.\n\nThe statement \"Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have presence of hot flashes for 30 days prior to study registration.\n\nThe secondary trial eligibility criteria do not mention any requirements for hot flashes.\n\nTherefore, it is not accurate to say that presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "70677d5f-7022-404c-8410-d1f89366d92f", "result": "Contradiction.\n\nThe statement \"the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts\" is a contradiction of the given trial information.\n\nThe primary trial outcome measurement is the number of patients with pathological complete response rate (pCR). The secondary trial outcome measurement is disease-free survival.\n\nNeither trial measures tumor diameter.\n\nTherefore, it is not accurate to say that the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "f46a7d27-a94f-4389-a1a0-4a8f5177b354", "result": "Contradiction.\n\nThe statement \"None of the individual Aes recorded in the primary trial affect more than than one patient\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that the following adverse events affect more than one patient:\n\n* Anemia (4 patients in cohort 1 and 0 patients in cohort 2)\n* Febrile neutropenia (3 patients in cohort 1 and 3 patients in cohort 2)\n* Abdominal pain (0 patients in cohort 1 and 2 patients in cohort 2)\n* Abdominal pain upper (0 patients in cohort 1 and 2 patients in cohort 2)\n\nTherefore, it is not accurate to say that none of the individual AEs recorded in the primary trial affect more than than one patient.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "fe876bb0-7ce3-4197-81ad-920f1f77938e", "result": "Entailment.\n\nThe statement \"there is a minimal difference between the results from the two the primary trial cohorts\" is an entailment of the given trial information.\n\nThe primary trial results show that the event-free survival rate in the exemestane arm was 88% (87 to 89%), and the event-free survival rate in the anastrozole arm was 89% (88 to 90%).\n\nThe difference between these two rates is only 1%.\n\nTherefore, it is accurate to say that there is a minimal difference between the results from the two the primary trial cohorts.\n\nHence, the statement is an entailment of the trial information."}
{"id": "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929", "result": "Contradiction.\n\nThe statement \"to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria do not mention anything about having a severe disability.\n\nTherefore, it is not accurate to say that to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "4f705481-5dd0-414c-b375-c56e8c235b42", "result": "Contradiction.\n\nThe statement \"The most common adverse event in the primary trial was skin infection\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that the most common adverse event was anemia, which occurred in 1 out of 41 patients (2.44%). Skin infection occurred in 2 out of 41 patients (4.88%).\n\nTherefore, it is not accurate to say that the most common adverse event in the primary trial was skin infection.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2", "result": "Contradiction.\n\nThe statement \"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that febrile neutropenia occurred in 3 out of 56 patients (5.36%). This is not the most common adverse event, and it did not affect most patients in the trial.\n\nTherefore, it is not accurate to say that febrile neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "c09fa61c-967a-40ae-96b0-c87b7cde237b", "result": "Entailment.\n\nThe statement \"None of the individual AEs recorded in the primary trial affect more than 10% of the population\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that the following adverse events affect more than 10% of the population:\n\n* Anemia (4% in cohort 1 and 0% in cohort 2)\n* Febrile neutropenia (3% in cohort 1 and 1.97% in cohort 2)\n\nAll other adverse events affect less than 10% of the population.\n\nTherefore, it is accurate to say that none of the individual AEs recorded in the primary trial affect more than 10% of the population.\n\nHence, the statement is an entailment of the trial information."}
{"id": "4309860d-042d-45a4-8a0a-a9fdd075247a", "result": "Contradiction.\n\nThe statement \"Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that in Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.\n\nTherefore, it is not accurate to say that Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85", "result": "Contradiction.\n\nThe statement \"the primary trial and the secondary trial use identical outcome measurements\" is a contradiction of the given trial information.\n\nThe primary trial outcome measurement is the overall response (complete response, partial response, or stable disease) of participants at 6 months.\n\nThe secondary trial outcome measurement is the percentage of participants with pathological complete response (pCR) in breast and axilla at the surgery visit (at approximately Weeks 14 to 19).\n\nTherefore, it is not accurate to say that the primary trial and the secondary trial use identical outcome measurements.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "59cd7909-00c3-4c23-9a08-a42dbc8eabdd", "result": "Entailment.\n\nThe statement \"Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants will be treated until disease progression.\n\nThis means that the number of cycles that each participant receives will vary depending on how long it takes for their disease to progress.\n\nTherefore, it is accurate to say that participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression.\n\nHence, the statement is an entailment of the trial information."}
{"id": "e6a4e9a6-56b8-4a30-9743-eb02688c090f", "result": "Entailment.\n\nThe statement \"A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that subjects with operable, node-positive or high-risk node-negative (see #3 below) HER2-positive breast carcinoma are eligible for the study.\n\nA patient with a node positive T2 N2 M0 adenocarcinoma of the breast meets the criteria of being operable and node-positive.\n\nA patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm meets the criteria of being operable and node-negative with a tumor >1 cm and negative estrogen receptor/progesterone receptor (ER/PR).\n\nTherefore, both patients would be eligible for the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "82a3e542-f784-44d7-90f6-34d7e969283c", "result": "Entailment.\n\nThe statement \"the primary trial participants receive more than one type of medication during the study\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that all patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.\n\nTherefore, it is accurate to say that the primary trial participants receive more than one type of medication during the study.\n\nHence, the statement is an entailment of the trial information."}
{"id": "fb360514-14be-45ab-8b74-ea5a7eb181d7", "result": "Entailment.\n\nThe statement \"the primary trial and the secondary trial do not report adverse events\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that the total number of adverse events is 0/23 (0.00%).\n\nThe secondary trial adverse events section shows that the total number of adverse events is 0/655 (0.00%) and 0/580 (0.00%).\n\nTherefore, it is accurate to say that the primary trial and the secondary trial do not report adverse events.\n\nHence, the statement is an entailment of the trial information."}
{"id": "7137dec6-5c98-4156-8035-7bbaaf0b649d", "result": "Entailment.\n\nThe statement \"ECOG score <2 is necessary to be eligible for the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 is required for eligibility.\n\nTherefore, it is accurate to say that ECOG score <2 is necessary to be eligible for the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "015dd869-db90-45a9-a951-9dc7dc2b2e01", "result": "Contradiction.\n\nThe statement \"patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients with cancer that has spread to the brain are not eligible for the trial.\n\nAdditionally, the criteria state that patients who have been treated for another cancer within the last 5 years are not eligible for the trial.\n\nTherefore, it is not accurate to say that patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "3a4003f6-ff1c-43d8-be48-f767266b2cf5", "result": "Entailment.\n\nThe statement \"the secondary trial and the primary trial do not have the same inclusion and exclusion conditions\" is an entailment of the given trial information.\n\nThe primary trial inclusion criteria include:\n\n* Female or male patients with diagnosis of invasive adenocarcinoma of the breast confirmed at MSKCC.\n* Evidence of recurrent or progressive locally advanced or metastatic breast cancer.\n* ECOG performance status of 0 or 1.\n* Age > or = to 18 years old.\n\nThe secondary trial inclusion criteria include:\n\n* Signed Informed Consent\n* ErbB2(HER2)overexpressing breast cancer.\n* Brain lesion(s) which are progressing.\n* Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS).\n* Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy.\n\nThe primary trial exclusion criteria include:\n\n* Life expectancy < 3 months.\n* Prior severe allergic reaction to paclitaxel therapy.\n* Presence of new or recurrent pleural effusion which is symptomatic and/or requiring medical intervention (NCI CTC Grade 2, 3 or 4).\n* Completion of previous chemotherapy regimen < 3 weeks prior to the start of study treatment.\n\nThe secondary trial exclusion criteria include:\n\n* Pregnant or lactating females.\n* Conditions that would effect the absorption of an oral drug.\n* History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents.\n* Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel.\n* Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent.\n\nTherefore, it is accurate to say that the secondary trial and the primary trial do not have the same inclusion and exclusion conditions.\n\nHence, the statement is an entailment of the trial information."}
{"id": "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7", "result": "Entailment.\n\nThe statement \"at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the median PFS in cohort 1 was 9.1 months (95% CI: 6.8 to 10.8 months), and the median PFS in cohort 2 was 7.1 months (95% CI: 5.6 to 10.8 months).\n\nTherefore, it is accurate to say that at least2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months.\n\nHence, the statement is an entailment of the trial information."}
{"id": "f3cb9150-32c6-4877-9a87-4fac45a24948", "result": "Entailment.\n\nThe statement \"Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 0 cases of Musculoskeletal adverse events.\n\nThe secondary trial adverse events section shows that there was 1 case of Musculoskeletal adverse events in cohort 2, and 0 cases in cohort 1.\n\nTherefore, it is accurate to say that between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "9d8b26d6-d574-4717-88b6-77458bc683f3", "result": "Contradiction.\n\nThe statement \"Syncope was the most common adverse event recorded in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that the most common adverse event was infection, which occurred in 2 out of 55 patients (3.64%). Syncope is not listed as an adverse event in the primary trial.\n\nTherefore, it is not accurate to say that syncope was the most common adverse event recorded in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "51be7c95-8da4-419c-950c-91ebdd2c3fe5", "result": "Contradiction.\n\nThe statement \"All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial\" is a contradiction of the given trial information.\n\nThe primary trial intervention section does not mention anything about BKM120 doses.\n\nThe secondary trial intervention section also does not mention anything about BKM120 doses.\n\nTherefore, it is not possible to compare the BKM120 doses between the two trials.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "07042b0f-d422-49c3-8d53-81319927a4b3", "result": "Contradiction.\n\nThe statement \"all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition.\n\nThe secondary trial eligibility criteria state that patients with metastatic or advanced solid tumors are eligible for the trial.\n\nTherefore, it is not accurate to say that all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, and there is no specific stage of cancer required for entry to the secondary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "32361e21-ee57-4c34-9390-833ba5048a10", "result": "Contradiction.\n\nThe statement \"the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks \u00b13 days thereafter.\n\nTherefore, it is not accurate to say that the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "88668508-dfd4-4a39-91cd-cf1654a6dfc4", "result": "Contradiction.\n\nThe statement \"the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis\" is a contradiction of the given trial information.\n\nThe primary trial results section does not mention anything about dermatitis.\n\nTherefore, it is not accurate to say that the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "dca4c9f7-bb2a-4f73-b390-93b7ced87c73", "result": "Entailment.\n\nThe statement \"The results from the secondary trial and the primary trial are non-comparable\" is an entailment of the given trial information.\n\nThe primary trial outcome measurement is the number of participants with complete pathologic response at 8 weeks.\n\nThe secondary trial outcome measurement is the change in Masood score from baseline to 6 months.\n\nTherefore, it is accurate to say that the results from the secondary trial and the primary trial are non-comparable.\n\nHence, the statement is an entailment of the trial information."}
{"id": "e7604382-09cd-43b4-998f-a51b33f25c5a", "result": "Entailment.\n\nThe statement \"the primary trial and the secondary trial participants do not receive any medication orally\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.\n\nThe secondary trial intervention section states that patients receive cetuximab IV over 60-120 minutes once a week.\n\nTherefore, it is accurate to say that the primary trial and the secondary trial participants do not receive any medication orally.\n\nHence, the statement is an entailment of the trial information."}
{"id": "75affd49-4905-4d43-9a5c-ef795281bac4", "result": "Entailment.\n\nThe statement \"neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the ORR in Arm A (liposomal doxorubicin) was 28% (16 to 42%).\n\nThe primary trial results section shows that the ORR in Arm B (docetaxel) was 31% (18 to 45%).\n\nTherefore, it is accurate to say that neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.\n\nHence, the statement is an entailment of the trial information."}
{"id": "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65", "result": "Contradiction.\n\nThe statement \"to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have confirmed hormone receptor positive advanced breast cancer, but they do not mention anything about prior chemotherapy.\n\nTherefore, it is not accurate to say that to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "8c6314f7-34f5-42a7-ba66-b95d050a6315", "result": "Contradiction.\n\nThe statement \"The shortest PFS in cohort 1 of the primary trial was 1.4 months below average\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that the median PFS in cohort 1 was 8.4 months (95% CI: 7.0 to 9.9 months).\n\nTherefore, it is not accurate to say that the shortest PFS in cohort 1 of the primary trial was 1.4 months below average.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "f114846e-79d8-4712-add0-bb34b65d418f", "result": "Contradiction.\n\nThe statement \"there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2\" is a contradiction of the given trial information.\n\nThe primary trial results section does not mention anything about deaths.\n\nTherefore, it is not possible to say that there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe", "result": "Contradiction.\n\nThe statement \"the primary trial reports the changes in the number of lesions for patients in its cohorts\" is a contradiction of the given trial information.\n\nThe primary trial results section does not mention anything about changes in the number of lesions.\n\nTherefore, it is not accurate to say that the primary trial reports the changes in the number of lesions for patients in its cohorts.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "b1d28450-fc7d-496a-9c7c-bf711b28f8e4", "result": "Contradiction.\n\nThe statement \"all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that pregnant women are excluded from the trial.\n\nTherefore, it is not accurate to say that all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3", "result": "Entailment.\n\nThe statement \"no cardiac or neural adverse events were recorded in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that the only adverse events that were recorded were Dry Eyes and Diarrhea.\n\nTherefore, it is accurate to say that no cardiac or neural adverse events were recorded in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "a805f174-2707-4302-a195-05153ea8523e", "result": "Entailment.\n\nThe statement \"Only adults can take part in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must be 18 years of age or older.\n\nTherefore, it is accurate to say that only adults can take part in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "e4aeb013-7713-4b73-acbd-f8379cc6a494", "result": "Contradiction.\n\nThe statement \"there was a higher percentage of patients with slipped disks in cohort2 of the primary trial than in cohort 1\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that there was 1 patient with a slipped disk in cohort 1 and 1 patient with a slipped disk in cohort 2.\n\nTherefore, it is not accurate to say that there was a higher percentage of patients with slipped disks in cohort2 of the primary trial than in cohort 1.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3", "result": "Entailment.\n\nThe statement \"All patients in cohort1 of the primary trial had a PFS of over7 months, with the highest PFS being just under 10 months\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the mean PFS in cohort 1 was 8.8 months (95% CI: 7.8 to9.8 months).\n\nTherefore, it is accurate to say that all patients in cohort1 of the primary trial had a PFS of over7 months, with the highest PFS being just under 10 months.\n\nHence, the statement is an entailment of the trial information."}
{"id": "2729a321-709b-4392-9604-dd7237bedb17", "result": "Entailment.\n\nThe statement \"the majority of participants in cohort1 and 2 of the primary trial achieved Disease-free Survival for 5 years\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the percentage of patients who achieved Disease-free Survival for 5 years in cohort 1 was 80.1% (78.0 to 82.0%).\n\nThe primary trial results section shows that the percentage of patients who achieved Disease-free Survival for 5 years in cohort 2 was 82.2% (80.2 to 84.0%).\n\nTherefore, it is accurate to say that the majority of participants in cohort1 and 2 of the primary trial achieved Disease-free Survival for 5 years.\n\nHence, the statement is an entailment of the trial information."}
{"id": "8e9611fc-89f8-44cb-af09-8d71a13ca082", "result": "Entailment.\n\nThe statement \"Cohort 1 and 2 of the primary trial do not receive the same intervention\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that in Group A, patients will receive NKTR-102, and in Group B, patients will receive Treatment of Physician's Choice (TPC).\n\nTherefore, it is accurate to say that Cohort 1 and 2 of the primary trial do not receive the same intervention.\n\nHence, the statement is an entailment of the trial information."}
{"id": "b9491012-49ba-4eb1-8230-1966f54ea012", "result": "Entailment.\n\nThe statement \"Patients with Extracranial metastases can be eligible for the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients with histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain are eligible for the trial.\n\nAdditionally, the criteria state that extracranial metastases are allowed.\n\nTherefore, it is accurate to say that patients with Extracranial metastases can be eligible for the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "62e449ad-16b3-479d-94a5-ffc435b5e99c", "result": "Entailment.\n\nThe statement \"patients with a Malignant brain tumour diagnosis are excluded from the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients with cancer that has spread to the brain are not eligible for the trial.\n\nTherefore, it is accurate to say that patients with a Malignant brain tumour diagnosis are excluded from the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "565d7982-aa9a-4c01-987c-1d67bc9c212d", "result": "Contradiction.\n\nThe statement \"ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients being treated with flucytosine are excluded from the trial.\n\nTherefore, it is not accurate to say that ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "7271e0db-bb82-423f-ad95-5ffa84fab97e", "result": "Entailment.\n\nThe statement \"There are more cases of Urosepsis in the primary trial than in the secondary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 2 cases of Urosepsis.\n\nThe secondary trial adverse events section shows that there were no cases of Urosepsis.\n\nTherefore, it is accurate to say that there are more cases of Urosepsis in the primary trial than in the secondary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "6402e13a-7cfb-4774-b7f9-80ecb79fda2a", "result": "Contradiction.\n\nThe statement \"the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that patients will receive Positron Emission Mammography, which involves various PEM views being performed on both the breast and axilla.\n\nThis indicates that the primary trial participants are administered some form of oral medication, as the PEM views are likely to involve the use of a radioactive tracer that is taken orally.\n\nTherefore, it is not accurate to say that the primary trial participants are not administered any oral medication.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "734423d5-4b47-4448-ab98-811015d626f0", "result": "Entailment.\n\nThe statement \"There were multiple patients which suffered Neutropenia in both cohorts of the primary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there was 1 patient with Neutropenia in cohort 1 and 1 patient with Neutropenia in cohort 2.\n\nTherefore, it is accurate to say that there were multiple patients which suffered Neutropenia in both cohorts of the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd", "result": "Contradiction.\n\nThe statement \"All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole\" is a contradiction of the given trial information.\n\nThe secondary trial intervention section states that patients in Phase 1 - Cohort A receive dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily.\n\nTherefore, it is not accurate to say that none of the secondary trial receive any Anastrazole.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "32ed503c-1cfd-44f6-b8bb-23d9d175d73d", "result": "Entailment.\n\nThe statement \"Patients must be able to undergo a PET scan to participate in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must be able to lie still for 1.5 hours for PET scanning.\n\nTherefore, it is accurate to say that patients must be able to undergo a PET scan to participate in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "175044aa-72b1-405d-8506-30002f5098e4", "result": "Contradiction.\n\nThe statement \"There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section does not mention anything about Hypotension, Hemorrhage or Bradycardia.\n\nTherefore, it is not accurate to say that the adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "045ad91e-44fa-42cc-ac22-a7aab26a9009", "result": "Contradiction.\n\nThe statement \"the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that all patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.\n\nIt does not mention anything about radiotherapy.\n\nTherefore, it is not accurate to say that the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "00822101-fa21-4a26-bf45-3b1f535da005", "result": "Entailment.\n\nThe statement \"a patient with a HER2-positive status can not take part in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients with HER2-positive status are not eligible for the study.\n\nTherefore, it is accurate to say that a patient with a HER2-positive status can not take part in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "06f798d1-2956-4903-83e9-58a41fa425f7", "result": "Entailment.\n\nThe statement \"the primary trial and the secondary trial do not record any cardiac or infection related adverse events\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 0/655 (0.00%) cardiac or infection related adverse events.\n\nThe secondary trial adverse events section shows that there were 0/15 (0.00%) and 0/16 (0.00%) cardiac or infection related adverse events.\n\nTherefore, it is accurate to say that the primary trial and the secondary trial do not record any cardiac or infection related adverse events.\n\nHence, the statement is an entailment of the trial information."}
{"id": "8648c7df-582a-42a9-9330-414b2430ac56", "result": "Contradiction.\n\nThe statement \"none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that Anemia affected 10 patients in cohort 1 and 8 patients in cohort 2.\n\nTherefore, it is not accurate to say that none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "89f610a7-9e81-43a4-8c1e-5503233b2be1", "result": "Contradiction.\n\nThe statement \"Breast cancer patients must have documented stable disease to participate in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have documented progressive disease.\n\nTherefore, it is not accurate to say that breast cancer patients must have documented stable disease to participate in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "b0046821-ba27-4a90-8869-cb708b843aa4", "result": "Contradiction.\n\nThe statement \"All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed\" is a contradiction of the given trial information.\n\nThe secondary trial intervention section states that patients in Phase 1 - Cohort A receive dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily.\n\nTherefore, it is not accurate to say that none of the secondary trial receive any flaxseed.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "d1b217ae-76f3-4ba6-958e-5b2558703ba4", "result": "Entailment.\n\nThe statement \"several cases of congestive heart failure in the primary trial occurred in cohort1, but none in cohort 2\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there was 1 case of congestive heart failure in cohort 1 and 0 cases in cohort 2.\n\nTherefore, it is accurate to say that several cases of congestive heart failure in the primary trial occurred in cohort1, but none in cohort 2.\n\nHence, the statement is an entailment of the trial information."}
{"id": "8ddf8b88-6e06-4c71-9e28-45f73a637af0", "result": "Contradiction.\n\nThe statement \"the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that patients will receive Positron Emission Mammography, which involves various PEM views being performed on both the breast and axilla.\n\nThis indicates that the primary trial participants are not administered any topical medication, as the PEM views are likely to involve the use of a radioactive tracer that is taken orally.\n\nTherefore, it is not accurate to say that the primary trial participants are administered oral and topical medication.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "0ea29bd5-20be-40ea-8ad7-705d283d1d48", "result": "Contradiction.\n\nThe statement \"the majority of participants in cohort1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that the percentage of patients alive and cancer-free in cohort 1 was 80.1% (78.0 to 82.0%).\n\nThe primary trial results section shows that the percentage of patients alive and cancer-free in cohort 2 was 82.2% (80.2 to 84.0%).\n\nTherefore, it is not accurate to say that the majority of participants in cohort1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "e147796d-2edd-42d1-ac53-300fb8bd5eb6", "result": "Contradiction.\n\nThe statement \"80% of patients in the primary trial received a placebo intervention\" is a contradiction of the given trial information.\n\nThe primary trial intervention section does not mention anything about the percentage of patients who received a placebo intervention.\n\nTherefore, it is not possible to say that 80% of patients in the primary trial received a placebo intervention.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "6b33b4ae-36f2-4a53-a954-6f246f6e023d", "result": "Entailment.\n\nThe statement \"Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have known and documented HER2-positive and known and documented LVEF of at least 50 percent (%).\n\nTherefore, it is accurate to say that patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%).\n\nHence, the statement is an entailment of the trial information."}
{"id": "06fad978-1dc3-46f5-b45f-5ac6577f28b9", "result": "Contradiction.\n\nThe statement \"Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have histologic or cytologic diagnosis of advanced breast cancer.\n\nThe secondary trial eligibility criteria state that patients must have confirmed hormone receptor positive advanced breast cancer.\n\nTherefore, it is not accurate to say that patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "878c09e7-3fd9-404e-921e-5b549e9578fb", "result": "Entailment.\n\nThe statement \"Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade4\" is an entailment of the given trial information.\n\nThe primary trial results section shows that 53 patients (75.7%) experienced a grade 1 adverse event.\n\nThe primary trial results section shows that 2 patients (2.9%) experienced a grade 4 adverse event.\n\nTherefore, it is accurate to say that most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade4.\n\nHence, the statement is an entailment of the trial information."}
{"id": "3a0c517d-9b9a-4497-9675-50ff12cd02b7", "result": "Entailment.\n\nThe statement \"in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 2 cases of Left ventricular dysfunction and 1 case of Abdominal pain in cohort 1.\n\nTherefore, it is accurate to say that in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain.\n\nHence, the statement is an entailment of the trial information."}
{"id": "9abb10d7-496e-44fd-915d-d86aedf6c9b6", "result": "Contradiction.\n\nThe statement \"Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least50 percent (%)\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have known and documented HER2-positive and known and documented LVEF of at least 50 percent (%).\n\nTherefore, it is not accurate to say that patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least50 percent (%).\n\nHence, the statement is a contradiction of the trial information."}
{"id": "8460a212-8054-4bd2-b4e6-af1d137a2f79", "result": "Entailment.\n\nThe statement \"the primary trial and the secondary trial report their results using different units of measure\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the objective response rate is reported as a percentage of participants.\n\nThe secondary trial results section shows that the proportion of sentinel lymph nodes flagged by the two methods is reported as a proportion of nodes.\n\nTherefore, it is accurate to say that the primary trial and the secondary trial report their results using different units of measure.\n\nHence, the statement is an entailment of the trial information."}
{"id": "a3390ae6-d41d-4dc7-899e-de9534adfd6b", "result": "Contradiction.\n\nThe statement \"the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that lapatinib was orally administered at 1250 milligrams (mg) once daily and capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily.\n\nTherefore, it is not accurate to say that the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "17bbea92-8f92-41f3-9b9d-cf6e62cf6798", "result": "Contradiction.\n\nThe statement \"the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that the dose limiting toxicity incidence of neratinib in combination with paclitaxel is reported as the number of participants who experienced dose limiting toxicity.\n\nIt does not report the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "794269ca-e7ec-4a65-ace5-b0f24a8cdc15", "result": "Entailment.\n\nThe statement \"the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the outcome measurement is the Percentage of Participants With Objective Response.\n\nThe secondary trial results section shows that the outcome measurement is Progression Free Survival.\n\nTherefore, it is accurate to say that the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS.\n\nHence, the statement is an entailment of the trial information."}
{"id": "4dfff980-6a2b-4f01-9194-6ec831d6fed7", "result": "Entailment.\n\nThe statement \"Infections were the most common adverse events recorded in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 2 cases of Infection and 1 case of Pain, Muscle Weakness and Dyspnea.\n\nTherefore, it is accurate to say that Infections were the most common adverse events recorded in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "dc4c57b0-8c75-494e-81b0-3528df85ebff", "result": "Contradiction.\n\nThe statement \"neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts\" is a contradiction of the given trial information.\n\nThe secondary trial results section shows that the outcome measurement is Overall Survival (OS) of Patients.\n\nTherefore, it is not accurate to say that neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c", "result": "Contradiction.\n\nThe statement \"the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response\" is a contradiction of the given trial information.\n\nThe primary trial results section does not mention anything about the definition of complete response.\n\nTherefore, it is not possible to say that the secondary trial and the primary trial use different definitions of complete response.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "251a20d8-2555-4929-9d01-c02311bdc93f", "result": "Entailment.\n\nThe statement \"a higher proportion of patients suffered Disease Progression or Death in cohort2 of the primary trial than in cohort 1\" is an entailment of the given trial information.\n\nThe primary trial results section shows that 35 patients in cohort 1 suffered Disease Progression or Death, and 40 patients in cohort 2 suffered Disease Progression or Death.\n\nTherefore, it is accurate to say that a higher proportion of patients suffered Disease Progression or Death in cohort2 of the primary trial than in cohort 1.\n\nHence, the statement is an entailment of the trial information."}
{"id": "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1", "result": "Entailment.\n\nThe statement \"the secondary trial and the primary trial do not record the same metrics in their results section\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the outcome measurement is LDex Change.\n\nThe secondary trial results section shows that the outcome measurement is Overall Survival (OS) of Patients.\n\nTherefore, it is accurate to say that the secondary trial and the primary trial do not record the same metrics in their results section.\n\nHence, the statement is an entailment of the trial information."}
{"id": "f0273b8c-460d-46fe-9c52-8ff4b08e439b", "result": "Entailment.\n\nThe statement \"eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that women >=18 years of age are eligible for the trial.\n\nTherefore, it is accurate to say that eliane is a56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8", "result": "Entailment.\n\nThe statement \"Breast cancer patients must have documented progressive disease to participate in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have pathologically confirmed diagnosis of breast cancer with documented progressive disease.\n\nTherefore, it is accurate to say that Breast cancer patients must have documented progressive disease to participate in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "c2217d42-e90c-4ffe-b084-e653b9ace4d5", "result": "Contradiction.\n\nThe statement \"the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that there were 0/655 (0.00%) cardiac or infection related adverse events.\n\nThe secondary trial adverse events section shows that there were 0/15 (0.00%) and 0/16 (0.00%) cardiac or infection related adverse events.\n\nHowever, neither the primary trial nor the secondary trial mention anything about epilepsy.\n\nTherefore, it is not accurate to say that the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "080da381-b5dd-46d3-99c4-18112da153c1", "result": "Contradiction.\n\nThe statement \"There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort1 of the secondary trial than in cohort 2 of the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section does not mention anything about Acute myocardial infarction, Cardiopulmonary failure or Supraventricular tachycardia.\n\nTherefore, it is not possible to say that there less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort1 of the secondary trial than in cohort 2 of the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "c100a7cd-e3a2-4901-a3e0-12336f769c7b", "result": "Contradiction.\n\nThe statement \"the secondary trial reported1 single case of Conjunctivitis, whereas the primary trial reported 16\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that there were 0/48 cases of Conjunctivitis.\n\nTherefore, it is not accurate to say that the secondary trial reported1 single case of Conjunctivitis, whereas the primary trial reported 16.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "ec1e269e-470d-43d9-8f23-8a19a5c96fcc", "result": "Contradiction.\n\nThe statement \"Anaemia was the most common adverse event in cohort1 of the primary trial and tachycardia was the most common in cohort2\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that Anaemia was the most common adverse event in cohort1 and in cohort2.\n\nTherefore, it is not accurate to say that Anaemia was the most common adverse event in cohort1 of the primary trial and tachycardia was the most common in cohort2.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "21611c2a-e6eb-4012-a209-9b6781e1f260", "result": "Contradiction.\n\nThe statement \"There is no adverse events section in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section is provided in the context.\n\nTherefore, it is not accurate to say that there is no adverse events section in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "d1b7105d-0b7d-4b10-92a7-d63243ff0629", "result": "Contradiction.\n\nThe statement \"Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients with Cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal) are excluded.\n\nThe secondary trial eligibility criteria do not mention anything about ejection fraction.\n\nTherefore, it is not accurate to say that Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are55 years of age or younger.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "7f3fe97e-68ee-470f-b06e-21cdddb67aa8", "result": "Contradiction.\n\nThe statement \"all participants of the primary trial have stage3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition.\n\nThe secondary trial eligibility criteria state that patients with metastatic or advanced solid tumors are eligible.\n\nTherefore, it is not accurate to say that all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "ce8464bd-951e-44aa-97d9-10b917b055ce", "result": "Contradiction.\n\nThe statement \"there was a significantly higher percentage of patients with slipped disks in cohort2 of the primary trial than in cohort 1\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that there was 1 case of Slipped disk in cohort 1 and 1 case in cohort 2.\n\nTherefore, it is not accurate to say that there was a significantly higher percentage of patients with slipped disks in cohort2 of the primary trial than in cohort 1.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "0131ebe3-746b-45a5-ba60-fdd326974fec", "result": "Contradiction.\n\nThe statement \"the primary trial and the secondary trial use comparable outcome measurements\" is a contradiction of the given trial information.\n\nThe primary trial outcome measurement is Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants.\n\nThe secondary trial outcome measurement is Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants).\n\nTherefore, it is not accurate to say that the primary trial and the secondary trial use comparable outcome measurements.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "b1dd7632-ed92-40a9-9293-bce68619c658", "result": "Contradiction.\n\nThe statement \"Patients with stage4 cancer are excluded from the primary trial, only patients with stage2 and 3 cancer can be eligible\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients with newly diagnosed with stage I-III cancer of the female breast are eligible.\n\nTherefore, it is not accurate to say that Patients with stage4 cancer are excluded from the primary trial, only patients with stage2 and 3 cancer can be eligible.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc", "result": "Entailment.\n\nThe statement \"the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that Fulvestrant was administered intramuscularly and Everolimus was administered orally.\n\nTherefore, it is accurate to say that the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally.\n\nHence, the statement is an entailment of the trial information."}
{"id": "4a15ec5e-4904-4f01-a0a2-c51e83c8c070", "result": "Entailment.\n\nThe statement \"the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the outcome measurement is the Severity of Dermatitis in Radiation Treatment Site.\n\nThe results are reported for two groups: the Curcumin C3 Complex cohort and the Placebo cohort.\n\nTherefore, it is accurate to say that the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort.\n\nHence, the statement is an entailment of the trial information."}
{"id": "b9e29ea8-6847-40d4-b5c3-81c496101695", "result": "Contradiction.\n\nThe statement \"All patients in cohort1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that the mean PFS for cohort 1 was 8.8 months, with a 95% confidence interval of 7.8 to 9.8 months.\n\nTherefore, it is not accurate to say that All patients in cohort1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "2a2c16a7-f427-4fdb-8153-94aac304e4b8", "result": "Contradiction.\n\nThe statement \"Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles\" is a contradiction of the given trial information.\n\nThe primary trial intervention section shows that patients in cohort 1 receive trastuzumab, doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and 5-fluorouracil.\n\nPatients in cohort 2 receive doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and 5-fluorouracil.\n\nTherefore, it is not accurate to say that patients receive the same types and dosages of medication throughout all 17 cycles.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "618a3ae1-b22c-4c35-86a6-190c1b5b5d21", "result": "Entailment.\n\nThe statement \"Patients must have a Life expectancy of at least1 year to enroll in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have Life expectancy 1 year.\n\nTherefore, it is accurate to say that Patients must have a Life expectancy of at least1 year to enroll in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "e62f5a3f-0091-4980-9822-db8f4dc2502a", "result": "Contradiction.\n\nThe statement \"the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that the mean RDS score for the Curcumin C3 Complex cohort was 2.6, while the mean RDS score for the Placebo cohort was 3.4.\n\nTherefore, it is not accurate to say that there is no difference in the results from these two cohorts.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "4a41ac73-538a-43e5-b7ce-8c8e2d56286e", "result": "Contradiction.\n\nThe statement \"Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieving adjuvant therapy\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have completed all systemic therapy (including endocrine therapy) at least 1 year ago.\n\nThe secondary trial eligibility criteria do not mention anything about endocrine therapy.\n\nTherefore, it is not accurate to say that Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieving adjuvant therapy.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "75a65913-5655-4377-b441-ecdd4dd75175", "result": "Entailment.\n\nThe statement \"Patients with stage4 cancer are excluded from the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must be newly diagnosed with stage I-III cancer of the female breast.\n\nTherefore, it is accurate to say that Patients with stage4 cancer are excluded from the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "1329dec6-fb2c-4219-9db6-3fef9d94b316", "result": "Contradiction.\n\nThe statement \"in cohort1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that there were 2 cases of Left ventricular dysfunction and 1 case of Abdominal pain in cohort 1.\n\nTherefore, it is not accurate to say that in cohort1 of the primary trial there were10 more cases of Left ventricular dysfunction than Abdominal pain.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "29b2fa29-5a76-4877-95bb-1a8de7973d33", "result": "Entailment.\n\nThe statement \"Only 6/67 patients in cohort1 of the primary trial suffered adverse events\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were a total of 6 adverse events in cohort 1.\n\nTherefore, it is accurate to say that Only 6/67 patients in cohort1 of the primary trial suffered adverse events.\n\nHence, the statement is an entailment of the trial information."}
{"id": "7edba90d-076d-4f55-b9d6-a1765ceb48bd", "result": "Contradiction.\n\nThe statement \"the primary trial and the secondary trial participants do not receive any medication by IV\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.\n\nThe secondary trial intervention section states that patients receive cetuximab IV over 60-120 minutes once a week.\n\nTherefore, it is not accurate to say that the primary trial and the secondary trial participants do not receive any medication by IV.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37", "result": "Contradiction.\n\nThe statement \"in the primary trial, patients that received Fulvestrant were much more likely to suffer Disease Progression or Death than patients receiving herceptin\" is a contradiction of the given trial information.\n\nThe primary trial results section does not mention anything about herceptin.\n\nTherefore, it is not possible to say that in the primary trial, patients that received Fulvestrant were much more likely to suffer Disease Progression or Death than patients receiving herceptin.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "1314146f-2869-4525-8034-7f732d238385", "result": "Entailment.\n\nThe statement \"none of the individual adverse events in the primary trial affect more than 100 patients\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that the maximum number of patients affected by any individual adverse event is 10.\n\nTherefore, it is accurate to say that none of the individual adverse events in the primary trial affect more than100 patients.\n\nHence, the statement is an entailment of the trial information."}
{"id": "7c7418d2-32d7-4517-874b-eb3db24ea16a", "result": "Entailment.\n\nThe statement \"to be eligible for the primary trial candidates must be over the age of18, have a Karnofsky score over80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must be between 18 years and 70 years, have a Karnofsky performance status index >80 %, and have adequate hepatic, renal and heart functions, and adequate hematology levels.\n\nTherefore, it is accurate to say that to be eligible for the primary trial candidates must be over the age of18, have a Karnofsky score over80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.\n\nHence, the statement is an entailment of the trial information."}
{"id": "1f6a14ae-e22b-4b40-b389-217570dbf38e", "result": "Entailment.\n\nThe statement \"50% of cohort2 patients in the primary trial suffered Dose Limiting Toxicities\" is an entailment of the given trial information.\n\nThe primary trial results section shows that there were 2 participants in cohort 2, and 1 of them suffered Dose Limiting Toxicities.\n\nTherefore, it is accurate to say that 50% of cohort2 patients in the primary trial suffered Dose Limiting Toxicities.\n\nHence, the statement is an entailment of the trial information."}
{"id": "5c1e360c-fd93-4dd4-b855-71ba416d34cb", "result": "Entailment.\n\nThe statement \"patients must be able to receive medication orally to participate in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must be able to swallow an oral medication.\n\nTherefore, it is accurate to say that patients must be able to receive medication orally to participate in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d", "result": "Contradiction.\n\nThe statement \"the primary trial and the secondary trial report the same types of adverse events\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that there were 0 cases of adverse events.\n\nThe secondary trial adverse events section shows that there were 0 cases of adverse events in cohort 1 and 0 cases of adverse events in cohort 2.\n\nTherefore, it is not accurate to say that the primary trial and the secondary trial report the same types of adverse events.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "48f516ff-abb4-4312-9b00-02f53fb16218", "result": "Contradiction.\n\nThe statement \"under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that 26 out of 32 patients in the intervention arm experienced Pathologic Complete Response.\n\nTherefore, it is not accurate to say that under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "978d19fc-e7f6-485e-b8bd-cfcde06441ab", "result": "Entailment.\n\nThe statement \"T1N0M0 patients are eligible for the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have histologically confirmed stage I, II, or III breast cancer and T1-3, N0-2, M0.\n\nTherefore, it is accurate to say that T1N0M0 patients are eligible for the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "0a6d1b4c-244e-44e2-a229-62e4cbdfa979", "result": "Entailment.\n\nThe statement \"the results of the secondary trial and the primary trial are non-comparable\" is an entailment of the given trial information.\n\nThe primary trial outcome measurement is the safety of external-beam PBI utilizing 40 Gy in ten daily fractions over two weeks.\n\nThe secondary trial outcome measurement is the overall tumor response.\n\nTherefore, it is accurate to say that the results of the secondary trial and the primary trial are non-comparable.\n\nHence, the statement is an entailment of the trial information."}
{"id": "9bcc31df-c1f6-4785-9235-f673213acf3a", "result": "Entailment.\n\nThe statement \"both the primary trial cohorts receive identical doses of Docetaxel\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants in both cohorts received docetaxel 100 mg/m^2 intravenously on Day1 of each 3 week cycle for a maximum of 27 weeks (9 cycles).\n\nTherefore, it is accurate to say that both the primary trial cohorts receive identical doses of Docetaxel.\n\nHence, the statement is an entailment of the trial information."}
{"id": "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9", "result": "Entailment.\n\nThe statement \"neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants in the Multivitamin Arm + Calcitriol Arm received a Calcitriol pill taken once per week, and participants in the Exercise Arm and Calcitriol+ Exercise Arm received Exercise consisting of progressive walking and resistance band training and a Calcitriol pill taken once per week.\n\nTherefore, it is accurate to say that neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention.\n\nHence, the statement is an entailment of the trial information."}
{"id": "75cf4ec2-9f2b-4d5b-8772-af247eaca07b", "result": "Entailment.\n\nThe statement \"Patients with Histologically confirmed breast cancer stageI-III are not eligible for the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have Histologically confirmed breast cancer that is estrogen receptor- (ER-) negative, PR-negative, and HER-2 nonoverexpressing by immunohistochemistry (0,1) or non-gene amplified by FISH performed upon the primary tumor or metastatic lesion.\n\nTherefore, it is accurate to say that Patients with Histologically confirmed breast cancer stageI-III are not eligible for the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "553f00ea-5197-4233-b1e0-e5727856b599", "result": "Contradiction.\n\nThe statement \"no cardiac or bowel-related adverse events were recorded in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that there was 1 case of Diarrhea in the trial.\n\nTherefore, it is not accurate to say that no cardiac or bowel-related adverse events were recorded in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32", "result": "Contradiction.\n\nThe statement \"There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS and Anemia in the secondary trial than in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section does not mention anything about mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS or Anemia.\n\nThe secondary trial adverse events section shows that there was 1 case of Anemia.\n\nTherefore, it is not accurate to say that There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS and Anemia in the secondary trial than in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "215a5c4a-d90c-4500-8284-0679ce311734", "result": "Entailment.\n\nThe statement \"patients must have HER2- breast cancer to participate in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have ErbB2(HER2)overexpressing breast cancer.\n\nTherefore, it is accurate to say that patients must have HER2- breast cancer to participate in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "e9a4bd91-f58b-4234-9037-75e0699d1bbd", "result": "Entailment.\n\nThe statement \"the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants received Study drug 190 mg/m^2 for 2 to 4 weeks.\n\nTherefore, it is accurate to say that the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate.\n\nHence, the statement is an entailment of the trial information."}
{"id": "7d52734c-0801-413d-9ae2-d190b972cde5", "result": "Contradiction.\n\nThe statement \"The results from the secondary trial and the primary trial can be compared by changing the units from days to months\" is a contradiction of the given trial information.\n\nThe primary trial outcome measurement time frame is 8 weeks, while the secondary trial outcome measurement time frame is 6 months.\n\nTherefore, it is not accurate to say that The results from the secondary trial and the primary trial can be compared by changing the units from days to months.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "5de9caeb-9dd5-4535-8fe3-289450d9c626", "result": "Contradiction.\n\nThe statement \"the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group\" is a contradiction of the given trial information.\n\nThe primary trial results show that the Lapatinib Plus Capecitabine group had 8 patients with CNS Metastases, while the Trastuzumab Plus Capecitabine group had 12 patients with CNS Metastases.\n\nTherefore, it is not accurate to say that the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "bebfc78e-b35f-4677-8342-9567a7e795a1", "result": "Entailment.\n\nThe statement \"There is one case of Diarrhea in the secondary trial and none in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 0 cases of Diarrhea.\n\nThe secondary trial adverse events section shows that there was 1 case of Diarrhea.\n\nTherefore, it is accurate to say that There is one case of Diarrhea in the secondary trial and none in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "faa65e54-aa04-4595-8dae-05cf00b4c887", "result": "Entailment.\n\nThe statement \"Only cohort1 patients of the primary trial are administered Ipatasertib\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants in INTERVENTION1 received ipatasertib orally daily on Days1-21 of each 28-day cycle for 3 cycles.\n\nTherefore, it is accurate to say that Only cohort1 patients of the primary trial are administered Ipatasertib.\n\nHence, the statement is an entailment of the trial information."}
{"id": "751fd763-89fa-4d52-8bda-f09b490a5e78", "result": "Entailment.\n\nThe statement \"there were no recorded deaths in the primary trial cohorts\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the outcome measurement is Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at12 Months or Clinical Disease Recurrence).\n\nThe results show that there were 6 patients event-free in the Fulvestrant + Anastrozole group and 7 patients event-free in the Anastrozole group.\n\nTherefore, it is accurate to say that there were no recorded deaths in the primary trial cohorts.\n\nHence, the statement is an entailment of the trial information."}
{"id": "c40fdf91-9f81-454a-bba9-ec5c950cef6e", "result": "Entailment.\n\nThe statement \"One patient cohort in the primary trial received a placebo intervention\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants in INTERVENTION2 received matching placebo orally once daily.\n\nTherefore, it is accurate to say that One patient cohort in the primary trial received a placebo intervention.\n\nHence, the statement is an entailment of the trial information."}
{"id": "31105b43-832b-48bc-a78d-ee90c155ca44", "result": "Entailment.\n\nThe statement \"Presence of hot flashes for 30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have Presence of hot flashes for 30 days prior to study registration.\n\nThe secondary trial eligibility criteria do not mention anything about hot flashes.\n\nTherefore, it is accurate to say that Presence of hot flashes for30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "49ba06b2-576d-4db2-80b6-51673416f2ba", "result": "Contradiction.\n\nThe statement \"the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts\" is a contradiction of the given trial information.\n\nThe primary trial outcome measurement is Percent Change in Net Influx Constant (Ki) by FLT PET.\n\nThe secondary trial outcome measurement is Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1).\n\nTherefore, it is not accurate to say that the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "3cb71095-8e01-40dc-bbf5-eeffed55f354", "result": "Contradiction.\n\nThe statement \"Patients with Histologically confirmed breast cancer stageI-IV are not eligible for the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have Metastatic breast cancer (Stage IV) with measurable disease by RECIST criteria.\n\nTherefore, it is not accurate to say that Patients with Histologically confirmed breast cancer stageI-IV are not eligible for the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "09fc4356-6154-427e-b710-ed5df6470aff", "result": "Contradiction.\n\nThe statement \"50% of cohort2 patients in the primary trial suffered Keratitis\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that there were 2 participants in cohort 2, and 0 of them suffered Keratitis.\n\nTherefore, it is not accurate to say that 50% of cohort2 patients in the primary trial suffered Keratitis.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "446f3c69-0de5-475c-a8e2-ff40ece90672", "result": "Entailment.\n\nThe statement \"Only patients with HER2+ve breast cancer are eligible for the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies.\n\nTherefore, it is accurate to say that Only patients with HER2+ve breast cancer are eligible for the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2", "result": "Entailment.\n\nThe statement \"the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects\" is an entailment of the given trial information.\n\nThe primary trial results section shows that there were 3 participants in the Neratinib 160 mg + Paclitaxel 80 mg/m group and 0 of them suffered Dose Limiting Toxicity.\n\nThe primary trial results section also shows that there were 5 participants in the Neratinib 240 mg + Paclitaxel 80 mg/m group and 0 of them suffered Dose Limiting Toxicity.\n\nTherefore, it is accurate to say that the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer0 side effects.\n\nHence, the statement is an entailment of the trial information."}
{"id": "f0e845f9-8991-45b5-a520-51e934756f7a", "result": "Entailment.\n\nThe statement \"The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of24 weeks.\n\nThe secondary trial intervention section states that the intervention is Sentinel Lymph Node Biopsy.\n\nTherefore, it is accurate to say that The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.\n\nHence, the statement is an entailment of the trial information."}
{"id": "a0065d58-e03b-4dd0-9c81-cbbf651a6d45", "result": "Contradiction.\n\nThe statement \"any patient eligible for the secondary trial will also be eligible for the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria include: Female or male patients with diagnosis of invasive adenocarcinoma of the breast confirmed at MSKCC.\n\nThe secondary trial eligibility criteria include: Signed Informed Consent, ErbB2(HER2)overexpressing breast cancer, Brain lesion(s) which are progressing.\n\nTherefore, it is not accurate to say that any patient eligible for the secondary trial will also be eligible for the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41", "result": "Contradiction.\n\nThe statement \"ECOG score >2 is necessary to be eligible for the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have Eastern Cooperative Oncology Group (ECOG) score of0 or 1.\n\nTherefore, it is not accurate to say that ECOG score >2 is necessary to be eligible for the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "973f090a-8967-4d75-bb8e-6166c868337c", "result": "Contradiction.\n\nThe statement \"cohort1 patients of the primary trial are administered higher doses of Ipatasertib and Placebo than cohort2 patients\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that participants in both INTERVENTION1 and INTERVENTION2 received the same doses of Ipatasertib and Placebo.\n\nTherefore, it is not accurate to say that cohort1 patients of the primary trial are administered higher doses of Ipatasertib and Placebo than cohort2 patients.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2", "result": "Contradiction.\n\nThe statement \"Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria do not mention anything about having several visible carcinomas in the stomach and neck areas.\n\nTherefore, it is not accurate to say that Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "1d1f57f8-85f7-448c-a4bb-15957da568fd", "result": "Entailment.\n\nThe statement \"the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants received Pemetrexed 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression.\n\nTherefore, it is accurate to say that the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression.\n\nHence, the statement is an entailment of the trial information."}
{"id": "9f7d476e-9db3-4c00-abe6-4c2f0160470a", "result": "Contradiction.\n\nThe statement \"under30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that 26 out of 32 patients in the intervention arm experienced Pathologic Complete Response.\n\nTherefore, it is not accurate to say that under30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d", "result": "Entailment.\n\nThe statement \"both the primary trial cohorts receive identical doses of Docetaxel, with cohort1 also receiving 100 mg/m^2 of Placebo\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants in both INTERVENTION1 and INTERVENTION2 received docetaxel 100 mg/m^2 intravenously on Day1 of each 3 week cycle for a maximum of 27 weeks (9 cycles).\n\nThe primary trial intervention section also states that participants in INTERVENTION1 received placebo to bevacizumab intravenously on Day1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.\n\nTherefore, it is accurate to say that both the primary trial cohorts receive identical doses of Docetaxel, with cohort1 also receiving 100 mg/m^2 of Placebo.\n\nHence, the statement is an entailment of the trial information."}
{"id": "3adcc8fc-b76b-407a-a006-729a13f571fb", "result": "Contradiction.\n\nThe statement \"both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort1 all being diagnosed with HER2 positive cancer and cohort2 being PR-\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that cohort1 patients receive Nivolumab + Daratumumab (TNBC), while cohort2 patients receive Nivolumab + Daratumumab (NSCLC).\n\nTherefore, it is not accurate to say that both cohorts of the primary trial receive identical interventions.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "68379456-775b-463b-bfdb-d8aa42c9124b", "result": "Entailment.\n\nThe statement \"Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have Females with histologic or cytologic diagnosis of advanced breast cancer.\n\nThe secondary trial eligibility criteria state that patients must have Confirmed hormone receptor positive advanced breast cancer, postmenopausal women.\n\nTherefore, it is accurate to say that Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb", "result": "Contradiction.\n\nThe statement \"Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago.\n\nThe secondary trial eligibility criteria do not mention anything about endocrine therapy.\n\nTherefore, it is not accurate to say that Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "f04d9695-81b8-4d70-877b-59caddf901bd", "result": "Entailment.\n\nThe statement \"Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort1 of the secondary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 0 cases of Dyspnea.\n\nThe secondary trial adverse events section shows that there was 1 case of Dyspnea in cohort1 and 0 cases of Dyspnea in cohort2.\n\nTherefore, it is accurate to say that Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort1 of the secondary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "f42e1874-343a-43ed-bb0c-884509c4793c", "result": "Contradiction.\n\nThe statement \"the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death\" is a contradiction of the given trial information.\n\nThe primary trial outcome measurement is Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]).\n\nThe secondary trial outcome measurement is Progression Free Survival (PFS) as defined as the period from the day of randomization until the first observation of lesion progression or death from any cause.\n\nTherefore, it is not accurate to say that the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "30483d7e-7703-459c-bd10-e2bd259c2a4f", "result": "Entailment.\n\nThe statement \"there were two types of Adverse events which did not affect any of the patients in cohort1 of the primary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 0 cases of Thrombocytopenia and 0 cases of Nausea in cohort1.\n\nTherefore, it is accurate to say that there were two types of Adverse events which did not affect any of the patients in cohort1 of the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "7cde9a22-a91f-4feb-892d-7cbd35f96a27", "result": "Entailment.\n\nThe statement \"the primary trial reports the changes in tumor size for patients in its cohorts\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the outcome measurement is Change in Tumor Size (CTS) From Baseline to the End of Cycle 2.\n\nTherefore, it is accurate to say that the primary trial reports the changes in tumor size for patients in its cohorts.\n\nHence, the statement is an entailment of the trial information."}
{"id": "16c29502-4683-4087-9410-ff1b786556f5", "result": "Contradiction.\n\nThe statement \"The least common adverse event in the primary trial was Constipation\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that the following adverse events occurred only once: Anemia, Febrile neutropenia, Eye disorders - Other, Visual disturbance, Abdominal pain, Nausea, Fever, Pain, Skin infection, Alkaline phosphatase increased, and Aspartate aminotransferase increased.\n\nConstipation occurred twice.\n\nTherefore, it is not accurate to say that The least common adverse event in the primary trial was Constipation.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "5c975af8-6b7f-4a5d-b4a6-257c76763ce9", "result": "Contradiction.\n\nThe statement \"There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort1 of the secondary trial than in the entire patient cohort of the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that there were 0 cases of Acute myocardial infarction, 0 cases of Cardiopulmonary failure, and 0 cases of Supraventricular tachycardia.\n\nThe secondary trial adverse events section shows that there was 1 case of Acute myocardial infarction, 0 cases of Cardiopulmonary failure, and 1 case of Supraventricular tachycardia in cohort1.\n\nTherefore, it is not accurate to say that There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort1 of the secondary trial than in the entire patient cohort of the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7", "result": "Entailment.\n\nThe statement \"There were more total AEs in cohort1 of the primary trial than cohort2\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 13 total AEs in cohort1 and 12 total AEs in cohort2.\n\nTherefore, it is accurate to say that There were more total AEs in cohort1 of the primary trial than cohort2.\n\nHence, the statement is an entailment of the trial information."}
{"id": "8e91e404-086e-4063-8d54-83d1b8ebd969", "result": "Entailment.\n\nThe statement \"over 1/6 patients in cohort1 of the primary trial suffered adverse events\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 10 patients in cohort1 who suffered adverse events out of a total of 67 patients.\n\nTherefore, it is accurate to say that over 1/6 patients in cohort1 of the primary trial suffered adverse events.\n\nHence, the statement is an entailment of the trial information."}
{"id": "b8322b23-a4f6-4cba-9761-be826b509de7", "result": "Entailment.\n\nThe statement \"There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 0 cases of Eye disorders, 0 cases of Abdominal pain, 0 cases of Febrile neutropenia, and 0 cases of Anemia.\n\nThe secondary trial adverse events section shows that there was 1 case of Eye disorders, 1 case of Abdominal pain, 1 case of Febrile neutropenia, and 1 case of Anemia.\n\nTherefore, it is accurate to say that There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3", "result": "Entailment.\n\nThe statement \"There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 11 different types of AEs in cohort1 and 10 different types of AEs in cohort2.\n\nThe secondary trial adverse events section shows that there was only 1 type of AE in cohort1 and 1 type of AE in cohort2.\n\nTherefore, it is accurate to say that There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts.\n\nHence, the statement is an entailment of the trial information."}
{"id": "4b97a844-8d52-48bb-8eda-ca205268f016", "result": "Contradiction.\n\nThe statement \"Patients must have a Life expectancy of75+ years to enroll in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must have Life expectancy 1 year.\n\nTherefore, it is not accurate to say that Patients must have a Life expectancy of75+ years to enroll in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "2a03c17f-3afe-40f1-a0db-4b876ee8c700", "result": "Entailment.\n\nThe statement \"the primary trial and the secondary trial have non-comparable outcome measurements for their results\" is an entailment of the given trial information.\n\nThe primary trial outcome measurement is Percent Change in Net Influx Constant (Ki) by FLT PET.\n\nThe secondary trial outcome measurement is Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1).\n\nTherefore, it is accurate to say that the primary trial and the secondary trial have non-comparable outcome measurements for their results.\n\nHence, the statement is an entailment of the trial information."}
{"id": "3ba42f68-a643-4d10-afd0-cbb358d05a6f", "result": "Contradiction.\n\nThe statement \"All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that patients in both INTERVENTION1 and INTERVENTION2 received paclitaxel.\n\nThe secondary trial intervention section does not mention anything about the doses of paclitaxel that patients received.\n\nTherefore, it is not accurate to say that All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "0a079cca-abde-42cf-9cec-a76e7a380e14", "result": "Entailment.\n\nThe statement \"neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention\" is an entailment of the given trial information.\n\nThe primary trial intervention section does not mention anything about surgery.\n\nTherefore, it is accurate to say that neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention.\n\nHence, the statement is an entailment of the trial information."}
{"id": "9c033072-5f94-4d79-af47-126d531f0d6e", "result": "Contradiction.\n\nThe statement \"There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section does not mention anything about Holocraneal cephale and Catheter - related infections.\n\nThe secondary trial adverse events section does not mention anything about Holocraneal cephale and Catheter - related infections.\n\nTherefore, it is not accurate to say that There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "a52b2d4f-0b06-4960-a9c3-88cb92df0980", "result": "Contradiction.\n\nThe statement \"the primary trial participants receive Capecitabine less often than they receive Lapatinib\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle.\n\nTherefore, it is not accurate to say that the primary trial participants receive Capecitabine less often than they receive Lapatinib.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb", "result": "Contradiction.\n\nThe statement \"eliane is a 56 year old woman, and alex is a32 year old man, both eliane and alex can both be eligible for the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that patients must be women >=18 years of age.\n\nTherefore, it is not accurate to say that eliane is a56 year old woman, and alex is a32 year old man, both eliane and alex can both be eligible for the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "1842904b-5371-49ee-b6f4-8831b879098b", "result": "Entailment.\n\nThe statement \"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than5% of patients\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 3 cases of Febrile Neutropenia out of a total of 56 patients.\n\nTherefore, it is accurate to say that Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than5% of patients.\n\nHence, the statement is an entailment of the trial information."}
{"id": "324562e6-2b61-4a07-b937-86f99689f2d5", "result": "Entailment.\n\nThe statement \"Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there were 5 cases of Diarrhoea out of a total of 65 patients.\n\nThe secondary trial adverse events section shows that there were 6 cases of Anaemia out of a total of 472 patients.\n\nTherefore, it is accurate to say that Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "74e376d7-5713-43f3-93f1-9608059c9547", "result": "Contradiction.\n\nThe statement \"neither of the interventions in the primary trial resulted in an Objective Benefit for more than40% of patients, in fact over86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that the ORR for Arm A -Liposomal Doxorubicin Then Docetaxel was 28 (16 to42) percent.\n\nThe primary trial results section shows that the ORR for Arm B - Docetaxel Then Liposomal Doxorubicin was 31 (18 to45) percent.\n\nThe primary trial results section does not mention anything about fatal complications.\n\nTherefore, it is not accurate to say that neither of the interventions in the primary trial resulted in an Objective Benefit for more than40% of patients, in fact over86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "0e609fad-9a28-4fb6-90b6-32a731e3b02c", "result": "Entailment.\n\nThe statement \"the primary trial and the secondary trial report their results as perecentages but use different units of measure\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the ORR was reported as a percentage of participants.\n\nThe secondary trial results section shows that the proportion of SLNs was reported as a proportion of nodes.\n\nTherefore, it is accurate to say that the primary trial and the secondary trial report their results as perecentages but use different units of measure.\n\nHence, the statement is an entailment of the trial information."}
{"id": "236780db-9e59-4dc9-8da0-e786287011cf", "result": "Contradiction.\n\nThe statement \"the primary trial intervention protocol lasts a total of14 days\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that Pemetrexed 600 mg/m2, intravenous (IV), every14 days until complete response or disease progression.\n\nTherefore, it is not accurate to say that the primary trial intervention protocol lasts a total of14 days.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "6d621974-c719-46df-8a50-d94e49583e33", "result": "Contradiction.\n\nThe statement \"all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization.\n\nTherefore, it is not accurate to say that all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "a9907a2e-254a-45ca-af50-3e44fd2f7af3", "result": "Entailment.\n\nThe statement \"There was one case of Neutropenia in both cohorts of the primary trial\" is an entailment of the given trial information.\n\nThe primary trial adverse events section shows that there was 1 case of Neutropenia in cohort1 and 1 case of Neutropenia in cohort2.\n\nTherefore, it is accurate to say that There was one case of Neutropenia in both cohorts of the primary trial.\n\nHence, the statement is an entailment of the trial information."}
{"id": "40f699a1-fbc6-40de-8e80-85b28f71632f", "result": "Contradiction.\n\nThe statement \"Most patients in the primary trial experienced a grade1 adverse events, the least common severity was grade5, which only affected8/70 patients\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that 53 patients experienced grade1 adverse events, and 12 patients experienced grade5 adverse events.\n\nTherefore, it is not accurate to say that Most patients in the primary trial experienced a grade1 adverse events, the least common severity was grade5, which only affected8/70 patients.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "6499b181-7a23-4073-8459-ad46ff02b20f", "result": "Contradiction.\n\nThe statement \"Participants of the primary trial will receive the intervention for a total of12 cycles (28 days)\" is a contradiction of the given trial information.\n\nThe primary trial intervention section states that Each treatment cycle is 28 days. Participants will be treated until disease progression.\n\nTherefore, it is not accurate to say that Participants of the primary trial will receive the intervention for a total of12 cycles (28 days).\n\nHence, the statement is a contradiction of the trial information."}
{"id": "2da13cd4-7189-4f85-be4d-5c1e213ae293", "result": "Contradiction.\n\nThe statement \"The most common AE in the primary trial was Non-cardiac chest pain, which affected less than5% of participants in cohort1\" is a contradiction of the given trial information.\n\nThe primary trial adverse events section shows that there were 2 cases of Non-cardiac chest pain in cohort1, which is not less than5% of the total number of participants in cohort1 (61).\n\nTherefore, it is not accurate to say that The most common AE in the primary trial was Non-cardiac chest pain, which affected less than5% of participants in cohort1.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "a9bb6de9-c6f8-4c99-81cd-f101cbaab387", "result": "Contradiction.\n\nThe statement \"Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain.\n\nTherefore, it is not accurate to say that Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7", "result": "Entailment.\n\nThe statement \"All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the outcome measurement was Complete Response + Partial Response + Stable Disease > 24 Weeks.\n\nThe primary trial results section also shows that all 35 patients were analyzed.\n\nTherefore, it is accurate to say that All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.\n\nHence, the statement is an entailment of the trial information."}
{"id": "016943fa-57ea-4293-8131-03292ea1836c", "result": "Entailment.\n\nThe statement \"A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over2cm\" is an entailment of the given trial information.\n\nThe primary trial eligibility criteria state that Subjects with operable, node-positive or high-risk node-negative (see #3 below) HER2-positive breast carcinoma are eligible for the study...\n\nThe primary trial eligibility criteria also state that Subjects must have been diagnosed with operable, histologically confirmed adenocarcinoma of the breast with no clinical or radiological evidence of metastatic disease but with otherwise high or intermediate risk tumor characteristics...\n\nThe primary trial eligibility criteria also state that node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR\n\nThe primary trial eligibility criteria also state that node-negative AND at least one of the following features:\n\nTumor >2 cm or\n\nTherefore, it is accurate to say that A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over2cm.\n\nHence, the statement is an entailment of the trial information."}
{"id": "402f0dbf-cf67-4425-b300-a0a3df4d59d3", "result": "Entailment.\n\nThe statement \"the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the outcome measurement was Objective Response Rate (ORR).\n\nThe secondary trial results section shows that the outcome measurement was Objective Response (OR).\n\nTherefore, it is accurate to say that the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions.\n\nHence, the statement is an entailment of the trial information."}
{"id": "62be4676-099f-4c42-8029-773af8fde6f7", "result": "Contradiction.\n\nThe statement \"Patients must be bedbound or severaly disabled to participate in the primary trial\" is a contradiction of the given trial information.\n\nThe primary trial eligibility criteria state that Able to lie still for 1.5 hours for PET scanning.\n\nTherefore, it is not accurate to say that Patients must be bedbound or severaly disabled to participate in the primary trial.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "1180dd58-61b8-4c48-ab00-7d458e68c85b", "result": "Contradiction.\n\nThe statement \"the results of the secondary trial and the primary trial report the same outcome measures\" is a contradiction of the given trial information.\n\nThe primary trial results section shows that the outcome measurement was Safety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks.\n\nThe secondary trial results section shows that the outcome measurement was Overall Tumor Response.\n\nTherefore, it is not accurate to say that the results of the secondary trial and the primary trial report the same outcome measures.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "566bdc2d-7c4a-4547-87da-ac81447ecca8", "result": "Contradiction.\n\nThe statement \"the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade3 or4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group\" is a contradiction of the given trial information.\n\nThe primary trial results section does not mention anything about Grade3 or4 skin/subcutaneous or pulmonary toxicities.\n\nTherefore, it is not accurate to say that the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade3 or4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "d310ec4e-993e-4827-8dc5-9aca053972db", "result": "Entailment.\n\nThe statement \"The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure\" is an entailment of the given trial information.\n\nThe primary trial intervention section states that participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of24 weeks.\n\nThe secondary trial intervention section states that the intervention is Sentinel Lymph Node Biopsy.\n\nTherefore, it is accurate to say that The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.\n\nHence, the statement is an entailment of the trial information."}
{"id": "a5617ae4-05a3-42d0-9e14-141de5f8c010", "result": "Entailment.\n\nThe statement \"the secondary trial reported1 single case of Conjunctivitis, whereas the primary trial did not report any\" is an entailment of the given trial information.\n\nThe primary trial adverse events section does not mention anything about Conjunctivitis.\n\nThe secondary trial adverse events section shows that there was 1 case of Conjunctivitis.\n\nTherefore, it is accurate to say that the secondary trial reported1 single case of Conjunctivitis, whereas the primary trial did not report any.\n\nHence, the statement is an entailment of the trial information."}
{"id": "42d1fcd3-8faa-4065-bbba-42cc90ab67fb", "result": "Entailment.\n\nThe statement \"the secondary trial and the primary trial do not both measure the pCR of their patient cohorts\" is an entailment of the given trial information.\n\nThe primary trial results section shows that the outcome measurement was Number of Patients With Pathological Complete Response Rate.\n\nThe secondary trial results section shows that the outcome measurement was Disease Free Survival.\n\nTherefore, it is accurate to say that the secondary trial and the primary trial do not both measure the pCR of their patient cohorts.\n\nHence, the statement is an entailment of the trial information."}
{"id": "d01fda83-5dc8-4ad5-92b8-7553dabd7046", "result": "Contradiction.\n\nThe statement \"the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse\" is a contradiction of the given trial information.\n\nThe primary trial results section states that the outcome measurement was Progression-free Survival (PFS).\n\nTherefore, it is not accurate to say that the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse.\n\nHence, the statement is a contradiction of the trial information."}
{"id": "985bc5a0-bc21-447f-92f1-150e23ede3f5", "result": "Contradiction.\n\nThe statement \"All the primary trial patients had a minimum of50% decrease in the sum of the longest diameter of target lesions\" is a contradiction of the given trial information.\n\nThe primary trial results section states that a patient has clinical benefit from treatment if CR + PR + SD >24 weeks.\n\nTherefore, it is not accurate to say that All the primary trial patients had a minimum of50% decrease in the sum of the longest diameter of target lesions.\n\nHence, the statement is a contradiction of the trial information."}
